HELX ETF (Franklin Genomic Advancements ETF) is managed by Franklin Templeton Investments (US) with $21.7M in net assets. HELX expense ratio is 0.50%, holding 65 positions across sectors including Unknown. Inception date: 2020-02-25.

HELX performance shows a YTD return of -5.34%. The 1-year return is 18.42% and the 5-year return is -4.99%.

HELX top holdings include Guardant Health Inc (7.2%), Natera Inc (6.3%), Krystal Biotech Inc (5.1%), Medpace Holdings Inc (4.5%), Bridgebio Pharma Inc (3.9%). View all HELX holdings, sector breakdown, or dividend history.

HELX can be compared against other funds using the overlap calculator or side-by-side comparison tool. HELX alternatives are available via the screener, along with tax-loss harvesting opportunities.